Barclays raised the firm’s price target on Arcellx to $62 from $49 and keeps an Overweight rating on the shares. Gilead and Arcellx this morning announced an expansion to their partnership, with Gilead opting in for BCMA Arc-SparX program for myeloma, and the companies expanding the CART-ddBCMA program to include lymphomas, the analyst tells investors in a research note. The firm says the timing and pricing bodes well for Arcellx’s near-term CART-ddBCMA update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACLX: